Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) have received a consensus recommendation of “Reduce” from the six analysts that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $1.40.
Several analysts recently weighed in on the company. Morgan Stanley decreased their price objective on Ginkgo Bioworks from $2.00 to $1.00 and set an “equal weight” rating for the company in a report on Wednesday, May 15th. William Blair cut shares of Ginkgo Bioworks from a “market perform” rating to an “underperform” rating in a research report on Friday, May 10th. BTIG Research dropped their price objective on shares of Ginkgo Bioworks from $0.50 to $0.20 and set a “sell” rating on the stock in a research note on Wednesday, June 26th. Finally, The Goldman Sachs Group reduced their price objective on shares of Ginkgo Bioworks from $0.80 to $0.30 and set a “sell” rating for the company in a research note on Tuesday, July 9th.
Read Our Latest Stock Report on DNA
Insider Buying and Selling
Hedge Funds Weigh In On Ginkgo Bioworks
Several hedge funds have recently made changes to their positions in DNA. Norges Bank acquired a new stake in Ginkgo Bioworks during the 4th quarter worth about $24,967,000. Vestmark Advisory Solutions Inc. purchased a new position in Ginkgo Bioworks during the 4th quarter worth approximately $5,044,000. Salem Investment Counselors Inc. lifted its stake in Ginkgo Bioworks by 110.6% during the 1st quarter. Salem Investment Counselors Inc. now owns 4,758,585 shares of the company’s stock valued at $5,520,000 after acquiring an additional 2,499,425 shares during the period. Lingotto Investment Management LLP boosted its holdings in shares of Ginkgo Bioworks by 34.9% in the 4th quarter. Lingotto Investment Management LLP now owns 8,511,301 shares of the company’s stock valued at $14,384,000 after acquiring an additional 2,200,000 shares during the last quarter. Finally, Cetera Investment Advisers increased its stake in shares of Ginkgo Bioworks by 2,683.7% in the first quarter. Cetera Investment Advisers now owns 2,264,107 shares of the company’s stock worth $2,626,000 after acquiring an additional 2,182,773 shares during the period. 78.63% of the stock is owned by institutional investors and hedge funds.
Ginkgo Bioworks Stock Performance
Shares of NYSE:DNA opened at $0.31 on Monday. The firm’s 50 day simple moving average is $0.40 and its 200-day simple moving average is $0.86. Ginkgo Bioworks has a one year low of $0.26 and a one year high of $2.47. The firm has a market cap of $695.67 million, a PE ratio of -0.72 and a beta of 1.14.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $37.94 million for the quarter, compared to analysts’ expectations of $45.50 million. Ginkgo Bioworks had a negative return on equity of 56.09% and a negative net margin of 409.11%. During the same quarter in the prior year, the firm earned ($0.08) earnings per share. Equities research analysts predict that Ginkgo Bioworks will post -0.3 EPS for the current fiscal year.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Articles
- Five stocks we like better than Ginkgo Bioworks
- Trading Stocks: RSI and Why it’s Useful
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.